Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06067230 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
A Phase 3 study of Respiratory Syncytial Virus, sponsored by ModernaTX.
- Active
- Registry status
- Phase 3
- Development phase
- 1,153
- Enrollment target
- 20
- Study locations
NCT06067230: Active Phase 3 study of Respiratory Syncytial Virus, sponsored by ModernaTX.
NCT06067230 is a Phase 3 study of Respiratory Syncytial Virus that is active but no longer recruiting, run by ModernaTX. The registered enrollment target is 1,153 participants, above the 232-participant average among 7 other Respiratory Syncytial Virus trials with a reported enrollment target (397% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06067230, a Phase 3 study of Respiratory Syncytial Virus, is active but no longer recruiting, sponsored by ModernaTX.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,153 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is divided into 2 parts (Part A and Part B). Part A of the study will evaluate the safety and immune response to mRNA-1345 in high-risk adults aged ≥18 to \<60 years. Part B of the study will evaluate the safety and immune response to mRNA-1345 in adults who received solid organ transplant (SOT).
Conditions Studied
Interventions
- BIOLOGICAL mRNA-1345
Study Locations (20)
Arizona
- Lenzmeier Family Medicine - CCT - PPDS - Glendale
- Foothills Research Center - CCT - PPDS - Phoenix
- Fiel Family & Sports Medicine - PC - CCT - PPDS - Tempe
Florida
- Excel Medical Clinical Trials DBA Flourish - Boca Raton
- Indago Research and Health Center - Hialeah
- CenExel RCA - Hollywood - Hollywood
California
- David Geffen School of Medicine at UCLA - Los Angeles
- Artemis Institute For Clinical Research LLC - San Diego - Headlands - PPDS - San Diego
Illinois
- University of Chicago - Chicago
- AES - DRS - Optimal Research Illinois - Peoria - Peoria
Michigan
- Henry Ford Hospital - Detroit
- DM Clinical Research - Southfield - ERN - PPDS - Southfield
Arkansas
- Baptist Health Center for Clinical Research - Little Rock
Colorado
- Critical Care, Pulmonary and Sleep Associates / CCT Research - Lakewood
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,153 participants |
| Start Date | 2023-10-06 |
| Est. Completion | 2026-07-30 |
| Phase | Phase 3 |
What the registry record for NCT06067230 still lists
NCT06067230 is an interventional study that assigns participants to a tested intervention. Its 1,153 participants enrollment target places it among the larger protocols in the corpus, above the 232-participant average among 7 other Respiratory Syncytial Virus trials with a reported enrollment target (397% higher).
The record links to 1 condition, with Respiratory Syncytial Virus appearing as the primary indexed condition, and to 1 intervention - of which mRNA-1345 is the first listed.
NCT06067230 names 20 study sites across 13 states, led by Arizona, Florida, California.
Frequently Asked Questions
What is clinical trial NCT06067230 about?
NCT06067230 is a clinical study titled "A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults". The study is divided into 2 parts (Part A and Part B). Part A of the study will evaluate the safety and immune response to mRNA-1345 in high-risk adults aged ≥18 to \<60 years. Part B of the study will evaluate the safety and immune response to mRNA-1345 in adults who received solid organ transplan...
What is the current status of trial NCT06067230?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,153 participants. The study started on 2023-10-06. Estimated completion is 2026-07-30.
What conditions does trial NCT06067230 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus.
What interventions are being tested in trial NCT06067230?
The interventions under investigation include: mRNA-1345 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06067230?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06067230 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
ACTIVE NOT RECRUITING · Phase 3
-
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
ACTIVE NOT RECRUITING · Phase 1
-
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
ACTIVE NOT RECRUITING · Phase 2
-
Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults
COMPLETED · Phase 1
-
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus
COMPLETED · Phase 2
-
A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04474301 · 1,152 participants
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
- NCT05564026 · 1,151 participants
Molecular Epidemiology of Pediatric Germ Cell Tumors
- NCT06408181 · 1,150 participants · Phase 3
APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
- NCT06528314 · 1,150 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI